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ABSTRACT 
 
Fingerroot (Boesenbergia pandurata (Roxb.) belongs to the family Zingiberaceae (Ginger). B. pandurata has 
pharmacological benefits such as neuroprotective, chemoprotective, anti-inflammatory, anti-angiogenic, antioxi-
dant, an inhibitor of protease enzyme NS2B/NS3 dengue virus, Japanese encephalitis virus and swine flu virus 
(H1N1). This study aims to determine the most effective compounds from B. pandurata as neuraminidase inhibi-
tors of H5N1 virus. The amino acid sequence for neuraminidase of avian influenza A virus subtype H5N1 of 
A/China/GD02/2006 (ABX57872.1) was retrieved from protein sequence database at NCBI. Then, modeled by 
Swiss Model. Analyse of molecular docking was performed using PyRx and the interactions between neuramini-
dase inhibitors of H5N1 and B. pandurata active compound was analyzed by PyMol software and LigPlot+ soft-
ware. From the 30 active compounds which have been docked, 4-hydroxypanduratin A, rubranine, boesenbergin 
B, boesenbergin A, 5,7-dimethoxyflavone, and tectochrysin had an equal or smaller free binding energy than con-
trol compound. 4-hydroxypanduratin A proved to be the most potent active compound as a neuraminidase inhibi-
tor (NA 1) because it has the most negative binding energy and the same amino acid binding residue with the 
control compound. Therefore, 4-hydroxypanduratin A is predicted to be used as inhibitors of neuraminidase in the 
H5N1 virus. 
 
Keywords:Boesenbergia pandurata, H5N1, neuraminidae, 4-hydroxypanduratin A.  
 
INTRODUCTION 
Avian Influenza A (H5N1) is one of the types of 
influenza virus which is the highest cause of pathogen-
ic death in humans [1]. This virus is still a major 
health problem in the world
 
[2] and also classified as 
highly pathogenic avian influenza (HPAI) which has 
caused a large number of deaths in humans and birds 
[3]. The threat of HPAI virus H5N1 needs further re-
search [4]. This virus belong to the family orthomyxo-
viridae which is enclosed by an envelope with a ge-
nome that composed of 8 different RNAs where each 
of RNAs enclosed by a single-stranded helical capsid 
[5]. 
The influenza envelope layer consists of two major 
glycoproteins: hemagglutinin (HA) and neuraminidase 
(NA) [6]. There are 16 serotypes hemagglutinin (H1-
H16) and 9 serotypes neuraminidase (N1-N9) [7]. 
Neuraminidase (NA) is a target protein that acts as a 
sialidase that divides sialic acid from cellular glycopro-
teins. Viral glycoproteins are expressed on infected 
cells and collected into virions. This mediates the ag-
gregation of newly born viral particles on the surface of 
the infected cell and allows the release of the virus [8]. 
Inhibition of neuraminidase (NA) is a way to limit 
the spread of infection from influenza virus [9]. Osel-
tamivir (tamiflu) and zanamivir (relenza) are neuram-
inidase inhibitors that are developed based on 
knowledge of the structure of the neuraminidase [10]. 
Oseltamivir is the first neuraminidase inhibitor drug 
used for treatment [11]. Nevertheless, it revealed that 
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the use of oseltamivir was unusable due to viral re-
sistance to the drug [12]. Then, a new metabolite com-
pounds from plants that can inhibit the activity of the 
virus are needed. 
Fingerroot (Boesenbergia pandurata (Roxb.)) be-
long to the Zingiberaceae family (Ginger) [13]. B. pan-
durata has pharmacological benefits such as neuropro-
tective, chemoprotective [14], anti-inflammatory [15], 
anti-angiogenic [16] antioxidant [17], inhibition of 
protease enzymes NS2B/NS3 in dengue virus [18], 
inhibition of  japanese encephalitis virus [19], and in-
hibition of the swine flu virus (H1N1) [2]. B. pandura-
ta contain several secondary metabolite compounds 
such as flavonoids, essential oils (EOs), and miscella-
neous compounds [13]. 
Treatment of Influenza A virus infection is still 
limited and the threat of a new pandemic from this 
infection still requires the development of the newest 
therapeutic agents [20]. Therefore, it is necessary to 
make a drug taken from a natural compounds of a 
plant that can be used against Avian Influenza A 
(H5N1). 
 
MATERIALS AND METHODS 
Protein Preparation and Modelling 
The amino acid sequence for neuraminidase of 
avian influenza A virus subtype H5N1 of 
A/China/GD02/2006 (ABX57872.1) was retrieved from 
protein sequence database at NCBI [21]. Molecular 
modeling of the target protein were determined using 
the Swiss Model website where the Swiss Model will 
show the best model of the sequnce of protein that we 
provide based on the percentage of the sequence identi-
ty [22]. Later on, the sequences are putted into the 
Swiss sequence target and modelled to obtain the ap-
propriate model. The model has been compared also to 
the neuraminidase (NA 1) protein model of some liter-
ature [6-8]. 
 
Ligan Preparation 
30 natural ligand compounds from B. pandurata 
and ligand control zanamivir structure collected from 
PubChem database (Table 1) [23]. The ligands is based 
on the similarity functions as antivirals. The ligands 
antiviral activity were analyzed by PASS Online Predic-
tion [24]. The ligand-like resemblance to the drug was 
selected by druglikeness based on Lipinski's rule of five 
(ROF) [25]. The preparation of the ligand involves 
adding hydrogen bonds, neutralizing the charge groups 
and removing the structure of the ligands. The opti-
mized ligand is used for molecular docking. 
 
Active Binding Site Prediction 
Binding site prediction of the target protein is per-
formed to find out which protein residues will be 
docked with ligand queries. The binding site prediction 
of the H5N1 viral neuraminidase (NA 1) protein was 
performed using the Zhang Cofactor website [26]. 
 
Molecular Docking 
The protein target and prepared ligands were 
docked by PyRx software [27]
 
and molecular docking 
was performed and resulted as a binding affinity score. 
Visualization performed using the PyMOL software 
[28]
 
 and Ligplot
+ 
software [29]. 
 
Table 1. Active compound from B. pandurata and Zamamivir 
as control 
Compounds CID Molecular 
formulae 
(-)-nicolaioidesin B 637029 C26H30O4 
(+)-Krachaizin A 11729201 C26H30O4 
(+/-)-isopanduratin A1 44444913 C26H30O4 
β-Ocimene 5281553 C10H16 
(2R)-8-
geranylpinostrobin 
23656470 C26H30O4 
4-hydroxypanduratin A 636530 C25H28O4 
5,6-Dehydrokawain 5273621 C14H12O3 
5,7-dimethoxyflavone 88881 C17H14O4 
Alpinetin 4053302 C16H14O4 
Boesenbergin A 23643133 C26H28O4 
Boesenbergin B 6313827 C26H28O4 
Camphor 2537 C10H16O 
Cardamonin 641785 C16H14O4 
Flavokawain A 5355469 C18H18O5 
Flavokawain B 5356121 C17H16O4 
Zanamivir 60855 C12H20N4O7 
Geraniol 637566 C10H18O 
Helichrysetin 6253344 C16H14O5 
Isopanduratin A 10069916 C26H30O4 
Methyl Cinnamate 637520 C10H10O2 
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Neral 643779 C10H16O 
Panduratin A 6483648 C26H30O4 
Panduratin C 6483647 C26H30O5 
Panduratin D 24864268 C28H30O4 
Pinocembrin 68071 C15H12O4 
Pinostrobin chalcone 5316793 C16H14O4 
Rotundaflavones Ia 101863268 C26H30O4 
Rubranine 42607681 C25H26O4 
Sakuranetin 73571 C16H14O5 
Tectochrysin 5281954 C16H12O4 
Uvangoletin 6483649 C16H16O4 
 
RESULTS AND DISCUSSION 
Potential Analysis of the B. pandurata Active Com-
pound as NA 1 Protein inhibitors.  
The analysis of the capability of inhibition of B. 
pandurata active compounds on NA 1 protein was 
done by molecular docking method, which simulated 
the binding of B. pandurata active compounds on NA 
1 protein, then compared with control compound 
known to inhibit NA 1 protein. This study used active 
compounds from B. pandurata as ligands obtained 
based on literature study results. Results from the liter-
ature study found 75 types of active compounds from 
the B. pandurata plant, which are included in flavo-
noids, essential oils (EO), and various compounds [13]. 
The active compounds of B. pandurata having a 
free binding energy equal to or less than the control 
are 4-hydroxypanduratin A, rubranine, boesenbergin B, 
boesenbergin A, 5,7-dimethoxyflavone, and tectochry-
sin. The six compounds have the lowest energy com-
pared with other compounds (Table 2). The binding 
energy of the active compounds were -9.7 kcal/mol for 
4-hydroxypanduratin A, -9.0 kcal/mol for rubranine, -
8.5 kcal/mol for boesenbergin B, -8.4 kcal/mol for 
boesenbergin A, -7,8 kcal/mol for 5,7-
dimethoxyflavone, and -7,7 kcal/mol for tectochrysin. 
Predicted compounds that have the potential to 
become neuraminidase inhibitors (NA1) in avian influ-
enza A from the six compounds that have free binding 
energy equal to or less than the control are 4-
hydroxypanduratin A. This compound has the most 
negative binding affinity (ΔGbind) energy of -9.7 
kcal/mol compared to the others. The more negative 
the affinity binding value (ΔGbind) indicates a good 
degree of stability between the ligand and the target 
protein, so that the bonds formed will be stronger [30]. 
 
Binding Side Analysis Between Ligand of Active Com-
pound of B. pandurata and Protein NA 1 
4-hydroxypanduratin A, rubranine, boesenbergin 
B, boesenbergin A, 5,7-dimethoxyflavone, and tecto-
chrysin had different binding sites with target protein 
(Figure 1). 4-hydroxypanduratin A compound has the 
side binding at the center and slightly to the right, 
rubranine has a lower left binding side, boesenbergin B 
has a central and slightly inward binding side of NA1 
protein, boesenbergin A and 5,7-dimethoxyflavone 
have the same binding sides with rubranine, and tecto-
chrysin has the side binding at the center and slightly 
to the left. 4-hydroxypanduratin A compound has a 
NA1 protein binding position similar to the control.  
Compounds that have the ability to have the same 
or almost the same binding side as the control indicate 
that the compound can act like a control [31]. 4-
hydroxypanduratin A has a binding position that is 
almost the same as the control. It shows that the 
compound is indicated to be capable of acting like a 
control. 
 
Analysis of Interaction Between Ligand of B. pandurata 
active compound and NA 1 Protein 
4-hydroxypanduratin A, rubranine, boesenbergin 
B, boesenbergin A, 5,7-dimethoxyflavone, and tecto-
chrysin had different interactions with protein NA 1 
(Table 3). 4-hydroxypanduratin A has the same three 
hydrophobic bonds as the controls: Arg205, Asn275, 
and Ile407, while rubranine and boesenbergin A have 
one hydrophobic bond similar to that of Ile407. The 
other three compounds, boesenbergin B, 5,7-
dimethoxyflavone, and tectochrysin, do not have the 
same hydrophobic bonds as controls. 
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Table 2. Potential inhibitor of active compound in B. pandurata against NA 1 protein 
Compounds 
Molecular 
formulae 
M.W 
(g/mo
l) 
Binding 
Affinity 
score 
(kcal/m
ol) 
Log P 
Hydrogen 
bond do-
nor 
Hydro-
gen 
bond 
accep-
tors 
Tar-
get 
Pro-
tein 
4-hydroxypanduratin A C25H28O4 392 -9.7 4.708601 3 4 NA 1 
Rubranine C25H26O4 390 -9.0 5.246600 1 4 NA 1 
Boesenbergin B C26H28O4 404 -8.5 6.207601 1 4 NA 1 
Boesenbergin A C26H28O4 404 -8.4 6.207601 1 4 NA 1 
5,7-dimethoxyflavone C17H14O4 282 -7.8 3.319999 0 4 NA 1 
Tectochrysin C16H12O4 268 -7.7 3.016999 1 4 NA 1 
Zanamivir C12H20N4O7 331 -7.7 5.120199 8 11 NA 1 
Cardamonin C16H14O4 270 -7.6 3.002499 2 4 NA 1 
Helichrysetin C16H14O5 286 -7.5 2.708099 3 5 NA 1 
Panduratin D C28H30O4 430 -7.6 7.052203 1 4 NA 1 
Pinostrobin chalcone C16H14O4 270 -7.6 3.002499 2 4 NA 1 
Flavokawain B C17H16O4 284 -7.6 3.305498 1 4 NA 1 
Panduratin C C26H30O5 422 -7.4 5.717201 3 5 NA 1 
Sakuranetin C16H14O5 286 -7.4 2.812899 2 5 NA 1 
Alpinetin C16H14O4 270 -7.3 3.107299 1 4 NA 1 
Panduratin A C26H30O4 404 -7.1 6.207601 1 4 NA 1 
Pinocembrin C15H12O4 256 -7.1 2.804299 2 4 NA 1 
Uvangoletin C16H16O4 272 -7.1 2.921899 2 4 NA 1 
Flavokawain A C18H18O5 314 -6.9 3.314099 1 5 NA 1 
 
4-hydroxypanduratin A had the same binding 
sites with a control of 99% because it had the same 3 
amino acid hydrogen bonds with the controls: Asp131, 
Arg132, and Tyr324, while rubranine, boesenbergin B, 
boesenbergin A, 5,7-dimethoxyflavone, and tectochry-
sin had a binding ability of 33% because the com-
pounds had only one amino acid hydrogen bond resi-
due equal to the control. Even though these com-
pounds have similar amino acids with control, they will 
not cause resistance to their use. This is because of the 
differences in compounds and constituents [33]. In 
addition, the 4-hydroxypanduratin A compound has a 
shorter hydrogen bond length compared to the con-
trols and also with the other. 4-hydroxypanduratin A  
 
 
has a hydrogen bond length of Asp131 (3.00 Å), 
Arg132 (2.02 Å), and Tyr324 (2.12 Å), rubranine has a  
hydrogen bond length Tyr324 (3.13 Å), boesenbergin B 
has a hydrogen bond length of Tyr324 (3.08Å), 
boesenbergin A has a hydrogen bond length Tyr324 
(3.03 Å), 5,7-dimethoxyflavone has a hydrogen bond 
length Tyr324 (2.89 Å), and tectochrysin has a hydro-
gen bond length of Tyr324 (2.88 Å), and and tecto-
chrysin have a binding ability of 33% because they 
have only 1 amino acid hydrogen bond residu equal to 
the control (Table 3). The active compound is predict-
ed have a stronger ability to inhibit the target protein if 
it has more amino acid binding residues equal the con-
trol compound [32].  
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Table 3. Interaction between active compound of B. pandurata and NA 1 protein 
Compounds Interaction 
4-hydroxypanduratin A Hydrogen bond (Length): Asp131 (3.00 Å), Arg132 (2.02 Å), Arg152 (2.77 Å), 
Tyr324 (2.12 Å) 
Hydrophobic bond: Arg205, Asn275, Ile407 
Rubranine Hydrogen bond (Length): Tyr324 (3.13 Å), Arg273 (3.21 Å) 
Hydrophobic bond: Trp379, Arg348, Ile407 
Boesenbergin B Hydrogen bond (Length):  Tyr324 (3.08Å) 
Hydrophobic bond: Ser160, Arg205, Tyr382 
Boesenbergin A Hydrogen bond (Length): Tyr324 (3.03 Å) 
Hydrophobic bond: Trp379, Arg348, Ile407, Lys412 
5,7-dimethoxyflavone Hydrogen bond (Length): Tyr324 (2.89 Å) 
Hydrophobic bond: Asn346, Arg348 
Tectochrysin Hydrogen bond (Length):  Tyr324 (2.88 Å) 
Hydrophobic bond: Arg348, Trp379,  Ile407 
Zanamivir Hydrogen bond (Length): Asp131 (3.10 Å), Arg132 (3.28 Å), Tyr324 (3.35 Å) 
Hydrophobic bond: Arg205, Asn275, Ile407 
  
In addition, the compound has the same binding 
site as controls on the amino acid residues with the 
length of the hydrogen bond residue in 4-
hydroxypanduratin A: Asp131 (3.00 Å), Arg132 (2.02 
Å), Tyr324 (2.12 Å), shorter if compared to Zanamivir 
compounds whose length hydrogen bond residues are:  
 
Asp131 (3.10 Å), Arg132 (3.28 Å), Tyr324 (3.35 
Å). The shorter the length hydrogen bond can make 
the interaction between the compound and the target 
protein faster [32]. Therefore, 4-hydroxypanduratin A 
compound is predicted have the ability to bind to NA 1 
protein so that it can inhibit the protein activities. 
 
 
 
 
 
 
 
 
 
 
 
 5,7-dimethoxyflavone – NA 
1 
 
4-hydroxypanduratin A – NA 1 
 
Rubranine – NA 1 
 
Zanamivir – NA 1 
 
Boesenbergin A – NA 
1 
 
Boesenbergin B – NA 1 
 
Tectochrysin – NA 1 
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CONCLUSION 
Some of the active compounds contained in B. 
pandurata are 4-hydroxypanduratin A, rubranine, 
boesenbergin B, boesenbergin A, 5,7-dimethoxyflavone, 
and tectochrysin are predicted to have the ability to 
inhibit neuraminidase in the H5N1 virus, especially the 
4-hydroxypanduratin A. 
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